Ключевые слова
Как цитировать
Аннотация
Данная статья является продолжением публикации, посвященной особым типам рака молочной железы (РМЖ), история изучения которого насчитывает тысячелетия. Современная онкология рассматривает РМЖ как гетерогенную группу заболеваний, различающихся по морфологии, молекулярным подтипам и клиническому течению. Благодаря развитию диагностики и персонализированной терапии, смертность от РМЖ существенно ниже, чем при других агрессивных опухолях, таких как рак поджелудочной железы или печени.
Во второй части публикации речь пойдет о редких и особых гистологических типах РМЖ с неблагоприятным и неясным прогнозом. Классификация этих форм основывается не только на морфологических, но и на иммуногистохимических, молекулярных и прогностических характеристиках, что отражает современный клинический подход.
В исследовании, проведенном на базе НМИЦ онкологии им. Н.Н. Петрова, частота особых типов РМЖ (без учета дольковых карцином) составила 8,12 % всех случаев, а наиболее часто встречались муцинозный и папиллярный типы, которые чаще характеризуются благоприятным прогнозом. Вместе с тем такие формы, как метапластический, нейроэндокринный и микропапиллярный рак ассоциированы с худшими исходами и составляют около трети всех особых форм.
Данные НМИЦ онкологии им. Н.Н. Петрова (Санкт-Петербург) сопоставимы с результатами анализа, представленного Научно-исследовательской онкологической клиникой при университетской клинике Анкары (Ankara Oncology Training and Research Hospital of the University of Health Sciences), что подтверждает универсальность выявленных закономерностей. Особые типы с благоприятным прогнозом, но трижды негативным фенотипом (например, аденокистозный, ацинарноклеточный, секреторный рак) требуют дальнейшего изучения из-за их редкости и потенциальной клинической значимости.
В заключении подчеркивается, что клиническое поведение особых форм РМЖ не всегда соответствует их биологическим особенностям, что затрудняет прогнозирование. Выбор терапии должен базироваться на комплексной оценке морфологических, иммуногистохимических и молекулярных характеристик опухоли, а также клинических данных. Персонализированный подход к лечению особых типов РМЖ становится ключевым фактором для улучшения исходов у данной категории пациентов.
Библиографические ссылки
Lukong K.E. Understanding breast cancer – The long and winding road. BBA Clinical. 2017: 7.
WHO classification of tumours. Breast Tumours. International Agency for Research on Cancer. 2019; 356.
Jenkins S., et al. Rare breast cancer subtypes. Current Oncology Reports. Springer. 2021; 23(5).
Al-Baimani K., et al. Invasive pleomorphic lobular carcinoma of the breast: Pathologic, clinical, and therapeutic considerations. Clinical Breast Cancer. 2015; 15(6).
Hoda S.A.F., et al. Rosen’s breast pathology. 5th edition. Philadelphia: Wolters Kluwer. 2021; 1.
Butler D., Rosa M. Pleomorphic lobular carcinoma of the breast: a morphologically and clinically distinct variant of lobular carcinoma. Archives of Pathology & Laboratory Medicine. 2013; 137(11).
Weigelt B., et al. The molecular underpinning of lobular histological growth pattern: a genome — wide transcriptomic analysis of invasive lobular carcinomas and grade‐ and molecular subtype — matched invasive ductal carcinomas of no special type. The Journal of Pathology. 2010; 220 (1): 45–57.
Tan P.H., et al. Histiocytoid breast carcinoma: an enigmatic lobular entity. J Clin Pathol. 2011; 64 (8): 654–659.
Sanli A.N., Kara H., Tekcan Sanli D.E., et al. Comparison of clinicopathologic features and survival outcomes of pleomorphic lobular, classical lobular, and invasive ductal carcinoma. World J Surg. 2025; 49 (6): 1406–1417.-DOI: 10.1002/wjs.12589.
Bell C. A system of operative surgery : founded on the basis of anatomy. Longman, Hurst, Rees, and Orme. London: Francis A. Countway Library of Medicine. 1807; 1.
Lee B.J., Tannenbaum E. Inflammatory carcinoma of the breast: a report of twenty-eight cases from the breast clinic of the Memorial Hospital. Surg Gynecol Obstet. 1924; 39: 580–595.
Dawood S., et al. International expert panel on inflammatory breast cancer: Consensus statement for standardized diagnosis and treatment. Annals of Oncology. 2011: 22(3).
Amin M.B. et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population — based to a more “personalized” approach to cancer staging. CA: A Cancer Journal for Clinicians. Wiley. 2017; 67 (2): 93–99.
Tschen E.H., Apisarnthanarax P. Inflammatory metastatic carcinoma of the breast. Arch Dermatol. 1981; 117(2): 120-121.
Wu S.G., et al. Inflammatory breast cancer outcomes by breast cancer subtype:A population-based study. Future Oncology. 2019; 15 (5).
Anderson W.F., Schairer C., Chen B.E., et al. Epidemiology of inflammatory breast cancer (IBC). Breast disease. 2005; 22: 9–23.-DOI: 10.3233/bd-2006-22103.
Dawood S., Ueno N.T., Valero V., et al. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer. 2011; 117 (9): 1819–1826.-DOI: 10.1002/cncr.25682.
Fisher E.R., et al. The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer. 1975; 36 (1): 1–85.
Kaufman M.W., et al. Carcinoma of the breast with pseudosarcomatous metaplasia. Cancer. 1984; 53 (9): 1908–1917.
Pezzi C.M., et al. Characteristics and treatment of metaplastic breast cancer: Analysis of 892 cases from the national cancer data base. Annals of Surgical Oncology. 2007; 14 (1).
Vranic U., Swensen S., Feldman J., et al. Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1. Journal of Clinical Pathology. 2017; 70 (3): 255-259.-DOI: 10.1136/jclinpath-2016-203874.
Bae S.Y., et al. The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients. Breast Cancer Research and Treatment. 2011; 126 (2).
Al-Hilli Z., Choong G., Keeney M.G., et al. Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy. Breast Cancer Research and Treatment. 2019; 176 (3): 709-716.-DOI: 10.1007/s10549-019-05264-2.
Adams S., Othus M., Patel S.P., et al. A multicenter phase II trial of ipilimumab and nivolumab in unresectable or metastatic metaplastic breast cancer: cohort 36 of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART, SWOG S1609). Clinical Cancer Research: an official journal of the American Association for Cancer Research. 2022; 28 (2): 271–278.-DOI: 10.1158/1078-0432.CCR-21-2182.
Tsang J.Y., Tse G.M. Breast cancer with neuroendocrine differentiation: an update based on the latest WHO classification. Mod Pathol. 2021; 34 (6): 1062–1073.-DOI: 10.1038/s41379-021-00736-7.
Wang J., et al. Invasive neuroendocrine carcinoma of the breast: A population-based study from the surveillance, epidemiology and end results (SEER) database. BMC Cancer. 2014; 14 (1).
Кудайбергенова А.Г., et al. Современные представления о нейроэндокринных опухолях/карциномах молочной железы. Онкопатология. 2018. Т. 1, № 2. [Kudaibergenova A.G., et al. Current views on neuroendocrine tumors/carcinomas of the breast. Oncopathology. 2018; 1 (2) (In Rus)].
Lavigne M., et al. Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast. Modern Pathology. 2018; 31 (1).
Wang J., et al. Invasive neuroendocrine carcinoma of the breast: A population-based study from the surveillance, epidemiology and end results (SEER) database. BMC Cancer. 2014; 14: 1.
Frame M.T., Gohal J., Mader K., Goodman J. Primary small cell carcinoma of the breast: an approach to medical and surgical management. Cureus. 2023; 15 (10): e47981.-DOI: 10.7759/cureus.47981.
Rakha E.A., et al. The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. European Journal of Cancer. 2009; 45: 10.
Pareja F., Selenica P., Brown D.N., et al. Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma. Histopathology. 2019; 75 (1): 139-145.-DOI: 10.1111/his.13853.
Verras G.I., Tchabashvili L., Mulita F., et al. Micropapillary breast carcinoma: from molecular pathogenesis to prognosis. Breast Cancer (Dove Medical Press). 2022; 14: 41-61.-DOI: 10.2147/BCTT.S346301.
Marchiò C., et al. Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. Journal of Pathology. 2008; 215 (4).
Qiu P., Cui Q., Huang S., et al. An overview of invasive micropapillary carcinoma of the breast: past, present, and future. Frontiers in Oncology. 2024; 14: 1435421.-DOI: 10.3389/fonc.2024.1435421.
Yun S.U., et al. Imaging findings of invasive micropapillary carcinoma of the breast. Journal of Breast Cancer. 2012; 15 (1).
Verras G.I., Tchabashvili L., Mulita F., et al. Micropapillary breast carcinoma: from molecular pathogenesis to prognosis. Breast Cancer (Dove Medical Press). 2022; 14: 41–61.-DOI: 10.2147/BCTT.S346301.
Aboumrad M.H., Horn R.C., Fine G. Lipid — secreting mammary carcinoma. Report of a case associated with paget's disease of the nipple. Cancer. 1963; 16 (4).
Ramos C.V., Taylor H.B. Lipid-rich carcinoma of the breast. A clinicopathologic analysis of 13 examples. Cancer. 1974; 33 (3): 812–819.
Zhang M., Pu D., Shi G., Li J. The clinical and pathological characteristics of lipid-rich carcinoma of the breast: an analysis of 98 published patients. BMC Women's Health. 2023; 23 (1): 301.-DOI: 10.1186/s12905-023-02449-2.
Balik E., Taneli C., Cetinkursun S., et al. Lipid secreting breast carcinoma in childhood: a case report. Eur J Pediatr Surg. 1993; 3 (1): 48-49.-DOI: 10.1055/s-2008-1063508.
Moritani S., et al. Intracytoplasmic lipid accumulation in apocrine carcinoma of the breast evaluated with adipophilin immunoreactivity: a possible link between apocrine carcinoma and lipid-rich carcinoma. Am J Surg Pathol. 2011; 35 (6): 861–867.
Ragazzi M., et al. Oncocytic carcinoma of the breast: Frequency, morphology and follow-up. Human Pathology. 2011: 42 (2).
Marucci G., Betts C.M., Frank G., Foschini M.P. Oncocytic meningioma: report of a case with progression after radiosurgery. Int J Surg Pathol. 2007; 15 (1): 77-81.-DOI: 10.1177/1066896906295824.
Lukovic J., Petrovic I., Liu Z., et al. Oncocytic papillary thyroid carcinoma and oncocytic poorly differentiated thyroid carcinoma: clinical features, uptake, and response to radioactive iodine therapy, and outcome. Front Endocrinol (Lausanne). 2021; 12: 795184.-DOI: 10.3389/fendo.2021.795184.
Alvarez Moreno J.C., He J. Invasive breast carcinoma with sebaceous morphologic pattern showing lymph node macrometastasis: a case report. Cureus. 2023; 15(4): e37365.-DOI: 10.7759/cureus.37365.
Cohen L.N., Flanagan C., Kong A.L., Cortina C.S. A systematic review of sebaceous carcinoma of the breast from 2000–2023: A rare entity with high recurrence rates. Surgical Oncology Insight. 2024; 1 (3): 100074.-DOI: 10.1016/j.soi.2024.100074.
de Alencar N.N., de Souza D.A., Lourenço A.A., da Silva R.R. Sebaceous breast carcinoma. Autopsy & Case Reports. 2022; 12: e2021365.-DOI: 10.4322/acr.2021.365.
Maia T., Amendoeira I. Breast sebaceous carcinoma — a rare entity. Clinico-pathological description of two cases and brief review. Virchows Archiv. 2018; 472 (5).
van Bogaert L.J., Maldague P. Histologic variants of lipid-secreting carcinoma of the breast. Virchows Archiv A Pathological Anatomy and Histology. 1977; 375 (4).
Zhou Z., et al. Clinical features, survival and prognostic factors of glycogen-rich clear cell carcinoma (GRCC) of the breast in the U.S. population. Journal of Clinical Medicine. 2019; 8 (2).
Eun N.L., et al. Clinical imaging of glycogen-rich clear cell carcinoma of the breast: A case series with literature review. Magnetic Resonance in Medical Sciences. 2019; 18 (3).
Singh G. R., Kumari M., Sunny K., et al. Interesting breast tumours: a tripod of cases. Nigerian Medical Journal: Journal of the Nigeria Medical Association. 2022; 65 (2): 222-230.-DOI: 10.60787/nmj-v65i2-312.
Zheng Y., Tang H., Liu Q., et al. Mutational analysis and protein expression of PI3K/AKT pathway in four mucinous cystadenocarcinoma of the breast. Diagnostic Pathology. 2025; 20 (1): 68.-DOI: 10.1186/s13000-025-01650-1.
Petersson F., et al. Mucinous cystadenocarcinoma of the breast with amplification of the HER2-gene confirmed by FISH: The first case reported. Human Pathology. 2010; 41 (6).
Sağdıç M.F., Özaslan C. Rare histological types of breast cancer: a single-center experience. Breast J. 2025; 9.
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2025